Translational Development Acquisition Corp. - Units (TDACU)

♥ 537 Thanks from members

Translational Development Acquisition Corp. (TDACU) exhibits mixed market sentiment, balancing a definitive merger agreement with ProLogium against bearish valuation models and declining year-over-year net income.

No chart available for this instrument.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Microchip Technology Incorporated (MCHP)

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

Entity & Market Metadata

Sector: Financials Industry: Shell Companies Founder: Translational Development Management Team Leadership: Management Team Leadership: Board of Directors Holder: Institutional SPAC Investors Holder: Private Equity Sponsors Blank Check Company Units IPO Shares #TDACU stock #Translational Development Acquisition Corp #SPAC #NASDAQ TDACU #units